File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results
  • Basic View
  • Metadata View
  • XML View
TitleAdefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results
 
AuthorsSchiff, E11
Lai, CL21
Hadziyannis, S58
Nuehaus, P
Terrault, N3
Colombo, M45
Tillmann, H30
Samuel, D2
Zuezem, S36
Villenueve, JP26
Arteburn, S33
BorrotoEsoda, K33
Brosgart, C33
Chuck, S33
Shakil, AO28
Fung, J28
Alberti, A5
Lok, A9
Picciotto, A15
Torre, F15
Riely, C7
Trepo, C49
Bizollon, T49
BottaaFridlund, D20
Gerolami, R20
Douglas, D35
Ranjan, D10
Faust, D8
Trojan, J8
Gane, E44
Villa, E29
Boarino, M29
Sokal, E25
Starkel, P25
Bonino, F39
Maurizio, B39
Gordon, F51
Pratt, J51
Berr, F22
Schiefke, I22
McCaughan, G24
Strasser, S24
Dusheiko, G1
Pageaux, GP48
Larrey, D48
Pastore, G18
Santantonio, T18
Alexander, G42
Woodall, T42
Van Vlierberghe, H57
Colle, I57
Harley, H54
Guggenheim, J56
MyxStaccini, A56
Metreau, JM52
Mavier, P52
Vierling, J55
Tran, T55
Girgrah, N37
Nyberg, L4
Yuen, MF40
Ma, M27
Balnco, MD17
Merli, M50
Tanzilli, P50
Angelico, M41
Di Paolo, D41
Rizzetto, M60
Marzano, A60
Lampertico, P45
Prieto, M38
Berenguer, M38
Felder, M34
Sterneck, M43
Willems, M43
Charlton, M13
Gunneson, T13
Ritter, M6
Voight, M19
Swift, J19
Shiffman, M32
Tassopoulos, N53
Klissas, I53
Naourmov, N1
Chamouard, P16
Marcellin, P59
Durand, F59
Angus, P46
Nathan, C46
Toniutto, P23
Fumo, E23
Andreone, P31
Cursaro, C31
Barcena, R14
Hoz, FG14
Zachoval, R47
Christina, M47
De Man, RA12
Metselaar, H12
 
Issue Date2007
 
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jtoc/106570021
 
CitationLiver Transplantation, 2007, v. 13 n. 3, p. 349-360 [How to Cite?]
DOI: http://dx.doi.org/10.1002/lt.20981
 
AbstractWait-listed (n = 226) or post-liver transplantation (n = 241) chronic hepatitis B (CHB) patients with lamivudine-resistant hepatitis B virus (HBV) were treated with adefovir dipivoxil for a median of 39 and 99 weeks, respectively. Among wait-listed patients, serum HBV DNA levels became undetectable (<l,000 copies/mL) in 59% and 65% at weeks 48 and 96, respectively. After 48 weeks, alanine aminotransferase (ALT), albumin, bilirubin, and prothrombin time normalized in 77%, 76%, 60%, and 84% of wait-listed patients, respectively. Among postransplantation patients, serum HBV DNA levels became undetectable in 40% and 65% at weeks 48 and 96, respectively. After 48 weeks, ALT, albumin, bilirubin, and prothrombin time normalized in 51%, 81%. 76%, and 56% of posttransplantation patients, respectively. Among wait-listed patients who underwent on-study liver transplantation, protection from graft reinfection over a median of 35 weeks was similar among parents who did (n = 34) or did not (n = 23) receive hepatitis B immunoglobulin (HBIg). Hepatitis B surface antigen was detected on the first measurement only in 6% and 9% of patiends who did or did not receive HBIg, respectively. Serum HBV DNA was detected on consecutive visits in 6% and 0% of patients who did or did not receive HBIg, respectively. Treatment-related adverse events led to discontinuation of adefovir dipivoxil in 4% of patients. Cumulative probabilities of resistance were 0%, 2%, and 2% at weeks 48, 96, and 144, respectively. In conclusion, adefovir dipivoxil is effective and safe at wait-listed or posttransplantation CHB patients with lamivudine-resistant HBV and prevents graft reinfection with or without HBIg. © 2007 AASLD.
 
ISSN1527-6465
2013 Impact Factor: 3.793
 
DOIhttp://dx.doi.org/10.1002/lt.20981
 
ISI Accession Number IDWOS:000244609200008
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorSchiff, E
 
dc.contributor.authorLai, CL
 
dc.contributor.authorHadziyannis, S
 
dc.contributor.authorNuehaus, P
 
dc.contributor.authorTerrault, N
 
dc.contributor.authorColombo, M
 
dc.contributor.authorTillmann, H
 
dc.contributor.authorSamuel, D
 
dc.contributor.authorZuezem, S
 
dc.contributor.authorVillenueve, JP
 
dc.contributor.authorArteburn, S
 
dc.contributor.authorBorrotoEsoda, K
 
dc.contributor.authorBrosgart, C
 
dc.contributor.authorChuck, S
 
dc.contributor.authorShakil, AO
 
dc.contributor.authorFung, J
 
dc.contributor.authorAlberti, A
 
dc.contributor.authorLok, A
 
dc.contributor.authorPicciotto, A
 
dc.contributor.authorTorre, F
 
dc.contributor.authorRiely, C
 
dc.contributor.authorTrepo, C
 
dc.contributor.authorBizollon, T
 
dc.contributor.authorBottaaFridlund, D
 
dc.contributor.authorGerolami, R
 
dc.contributor.authorDouglas, D
 
dc.contributor.authorRanjan, D
 
dc.contributor.authorFaust, D
 
dc.contributor.authorTrojan, J
 
dc.contributor.authorGane, E
 
dc.contributor.authorVilla, E
 
dc.contributor.authorBoarino, M
 
dc.contributor.authorSokal, E
 
dc.contributor.authorStarkel, P
 
dc.contributor.authorBonino, F
 
dc.contributor.authorMaurizio, B
 
dc.contributor.authorGordon, F
 
dc.contributor.authorPratt, J
 
dc.contributor.authorBerr, F
 
dc.contributor.authorSchiefke, I
 
dc.contributor.authorMcCaughan, G
 
dc.contributor.authorStrasser, S
 
dc.contributor.authorDusheiko, G
 
dc.contributor.authorPageaux, GP
 
dc.contributor.authorLarrey, D
 
dc.contributor.authorPastore, G
 
dc.contributor.authorSantantonio, T
 
dc.contributor.authorAlexander, G
 
dc.contributor.authorWoodall, T
 
dc.contributor.authorVan Vlierberghe, H
 
dc.contributor.authorColle, I
 
dc.contributor.authorHarley, H
 
dc.contributor.authorGuggenheim, J
 
dc.contributor.authorMyxStaccini, A
 
dc.contributor.authorMetreau, JM
 
dc.contributor.authorMavier, P
 
dc.contributor.authorVierling, J
 
dc.contributor.authorTran, T
 
dc.contributor.authorGirgrah, N
 
dc.contributor.authorNyberg, L
 
dc.contributor.authorYuen, MF
 
dc.contributor.authorMa, M
 
dc.contributor.authorBalnco, MD
 
dc.contributor.authorMerli, M
 
dc.contributor.authorTanzilli, P
 
dc.contributor.authorAngelico, M
 
dc.contributor.authorDi Paolo, D
 
dc.contributor.authorRizzetto, M
 
dc.contributor.authorMarzano, A
 
dc.contributor.authorLampertico, P
 
dc.contributor.authorPrieto, M
 
dc.contributor.authorBerenguer, M
 
dc.contributor.authorFelder, M
 
dc.contributor.authorSterneck, M
 
dc.contributor.authorWillems, M
 
dc.contributor.authorCharlton, M
 
dc.contributor.authorGunneson, T
 
dc.contributor.authorRitter, M
 
dc.contributor.authorVoight, M
 
dc.contributor.authorSwift, J
 
dc.contributor.authorShiffman, M
 
dc.contributor.authorTassopoulos, N
 
dc.contributor.authorKlissas, I
 
dc.contributor.authorNaourmov, N
 
dc.contributor.authorChamouard, P
 
dc.contributor.authorMarcellin, P
 
dc.contributor.authorDurand, F
 
dc.contributor.authorAngus, P
 
dc.contributor.authorNathan, C
 
dc.contributor.authorToniutto, P
 
dc.contributor.authorFumo, E
 
dc.contributor.authorAndreone, P
 
dc.contributor.authorCursaro, C
 
dc.contributor.authorBarcena, R
 
dc.contributor.authorHoz, FG
 
dc.contributor.authorZachoval, R
 
dc.contributor.authorChristina, M
 
dc.contributor.authorDe Man, RA
 
dc.contributor.authorMetselaar, H
 
dc.date.accessioned2010-09-06T07:21:01Z
 
dc.date.available2010-09-06T07:21:01Z
 
dc.date.issued2007
 
dc.description.abstractWait-listed (n = 226) or post-liver transplantation (n = 241) chronic hepatitis B (CHB) patients with lamivudine-resistant hepatitis B virus (HBV) were treated with adefovir dipivoxil for a median of 39 and 99 weeks, respectively. Among wait-listed patients, serum HBV DNA levels became undetectable (<l,000 copies/mL) in 59% and 65% at weeks 48 and 96, respectively. After 48 weeks, alanine aminotransferase (ALT), albumin, bilirubin, and prothrombin time normalized in 77%, 76%, 60%, and 84% of wait-listed patients, respectively. Among postransplantation patients, serum HBV DNA levels became undetectable in 40% and 65% at weeks 48 and 96, respectively. After 48 weeks, ALT, albumin, bilirubin, and prothrombin time normalized in 51%, 81%. 76%, and 56% of posttransplantation patients, respectively. Among wait-listed patients who underwent on-study liver transplantation, protection from graft reinfection over a median of 35 weeks was similar among parents who did (n = 34) or did not (n = 23) receive hepatitis B immunoglobulin (HBIg). Hepatitis B surface antigen was detected on the first measurement only in 6% and 9% of patiends who did or did not receive HBIg, respectively. Serum HBV DNA was detected on consecutive visits in 6% and 0% of patients who did or did not receive HBIg, respectively. Treatment-related adverse events led to discontinuation of adefovir dipivoxil in 4% of patients. Cumulative probabilities of resistance were 0%, 2%, and 2% at weeks 48, 96, and 144, respectively. In conclusion, adefovir dipivoxil is effective and safe at wait-listed or posttransplantation CHB patients with lamivudine-resistant HBV and prevents graft reinfection with or without HBIg. © 2007 AASLD.
 
dc.description.natureLink_to_subscribed_fulltext
 
dc.identifier.citationLiver Transplantation, 2007, v. 13 n. 3, p. 349-360 [How to Cite?]
DOI: http://dx.doi.org/10.1002/lt.20981
 
dc.identifier.doihttp://dx.doi.org/10.1002/lt.20981
 
dc.identifier.epage360
 
dc.identifier.hkuros131794
 
dc.identifier.isiWOS:000244609200008
 
dc.identifier.issn1527-6465
2013 Impact Factor: 3.793
 
dc.identifier.issue3
 
dc.identifier.openurl
 
dc.identifier.pmid17326221
 
dc.identifier.scopuseid_2-s2.0-33947427581
 
dc.identifier.spage349
 
dc.identifier.urihttp://hdl.handle.net/10722/76418
 
dc.identifier.volume13
 
dc.languageeng
 
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jtoc/106570021
 
dc.publisher.placeUnited States
 
dc.relation.ispartofLiver Transplantation
 
dc.relation.referencesReferences in Scopus
 
dc.rightsLiver Transplantation. Copyright © John Wiley & Sons, Inc.
 
dc.subject.meshAdenine - adverse effects - analogs & derivatives - therapeutic use
 
dc.subject.meshAdult
 
dc.subject.meshAntiviral Agents - adverse effects - therapeutic use
 
dc.subject.meshDNA, Viral - blood
 
dc.subject.meshDrug Resistance, Viral
 
dc.subject.meshDrug Therapy, Combination
 
dc.subject.meshFemale
 
dc.subject.meshHepatitis B - blood - drug therapy - prevention & control
 
dc.subject.meshHepatitis B virus - genetics
 
dc.subject.meshHumans
 
dc.subject.meshKidney Diseases - chemically induced
 
dc.subject.meshLamivudine - adverse effects - therapeutic use
 
dc.subject.meshLiver Transplantation - adverse effects - methods
 
dc.subject.meshMale
 
dc.subject.meshMiddle Aged
 
dc.subject.meshPhosphonic Acids - adverse effects - therapeutic use
 
dc.subject.meshProspective Studies
 
dc.subject.meshRecurrence - prevention & control
 
dc.subject.meshWaiting Lists
 
dc.titleAdefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Schiff, E</contributor.author>
<contributor.author>Lai, CL</contributor.author>
<contributor.author>Hadziyannis, S</contributor.author>
<contributor.author>Nuehaus, P</contributor.author>
<contributor.author>Terrault, N</contributor.author>
<contributor.author>Colombo, M</contributor.author>
<contributor.author>Tillmann, H</contributor.author>
<contributor.author>Samuel, D</contributor.author>
<contributor.author>Zuezem, S</contributor.author>
<contributor.author>Villenueve, JP</contributor.author>
<contributor.author>Arteburn, S</contributor.author>
<contributor.author>BorrotoEsoda, K</contributor.author>
<contributor.author>Brosgart, C</contributor.author>
<contributor.author>Chuck, S</contributor.author>
<contributor.author>Shakil, AO</contributor.author>
<contributor.author>Fung, J</contributor.author>
<contributor.author>Alberti, A</contributor.author>
<contributor.author>Lok, A</contributor.author>
<contributor.author>Picciotto, A</contributor.author>
<contributor.author>Torre, F</contributor.author>
<contributor.author>Riely, C</contributor.author>
<contributor.author>Trepo, C</contributor.author>
<contributor.author>Bizollon, T</contributor.author>
<contributor.author>BottaaFridlund, D</contributor.author>
<contributor.author>Gerolami, R</contributor.author>
<contributor.author>Douglas, D</contributor.author>
<contributor.author>Ranjan, D</contributor.author>
<contributor.author>Faust, D</contributor.author>
<contributor.author>Trojan, J</contributor.author>
<contributor.author>Gane, E</contributor.author>
<contributor.author>Villa, E</contributor.author>
<contributor.author>Boarino, M</contributor.author>
<contributor.author>Sokal, E</contributor.author>
<contributor.author>Starkel, P</contributor.author>
<contributor.author>Bonino, F</contributor.author>
<contributor.author>Maurizio, B</contributor.author>
<contributor.author>Gordon, F</contributor.author>
<contributor.author>Pratt, J</contributor.author>
<contributor.author>Berr, F</contributor.author>
<contributor.author>Schiefke, I</contributor.author>
<contributor.author>McCaughan, G</contributor.author>
<contributor.author>Strasser, S</contributor.author>
<contributor.author>Dusheiko, G</contributor.author>
<contributor.author>Pageaux, GP</contributor.author>
<contributor.author>Larrey, D</contributor.author>
<contributor.author>Pastore, G</contributor.author>
<contributor.author>Santantonio, T</contributor.author>
<contributor.author>Alexander, G</contributor.author>
<contributor.author>Woodall, T</contributor.author>
<contributor.author>Van Vlierberghe, H</contributor.author>
<contributor.author>Colle, I</contributor.author>
<contributor.author>Harley, H</contributor.author>
<contributor.author>Guggenheim, J</contributor.author>
<contributor.author>MyxStaccini, A</contributor.author>
<contributor.author>Metreau, JM</contributor.author>
<contributor.author>Mavier, P</contributor.author>
<contributor.author>Vierling, J</contributor.author>
<contributor.author>Tran, T</contributor.author>
<contributor.author>Girgrah, N</contributor.author>
<contributor.author>Nyberg, L</contributor.author>
<contributor.author>Yuen, MF</contributor.author>
<contributor.author>Ma, M</contributor.author>
<contributor.author>Balnco, MD</contributor.author>
<contributor.author>Merli, M</contributor.author>
<contributor.author>Tanzilli, P</contributor.author>
<contributor.author>Angelico, M</contributor.author>
<contributor.author>Di Paolo, D</contributor.author>
<contributor.author>Rizzetto, M</contributor.author>
<contributor.author>Marzano, A</contributor.author>
<contributor.author>Lampertico, P</contributor.author>
<contributor.author>Prieto, M</contributor.author>
<contributor.author>Berenguer, M</contributor.author>
<contributor.author>Felder, M</contributor.author>
<contributor.author>Sterneck, M</contributor.author>
<contributor.author>Willems, M</contributor.author>
<contributor.author>Charlton, M</contributor.author>
<contributor.author>Gunneson, T</contributor.author>
<contributor.author>Ritter, M</contributor.author>
<contributor.author>Voight, M</contributor.author>
<contributor.author>Swift, J</contributor.author>
<contributor.author>Shiffman, M</contributor.author>
<contributor.author>Tassopoulos, N</contributor.author>
<contributor.author>Klissas, I</contributor.author>
<contributor.author>Naourmov, N</contributor.author>
<contributor.author>Chamouard, P</contributor.author>
<contributor.author>Marcellin, P</contributor.author>
<contributor.author>Durand, F</contributor.author>
<contributor.author>Angus, P</contributor.author>
<contributor.author>Nathan, C</contributor.author>
<contributor.author>Toniutto, P</contributor.author>
<contributor.author>Fumo, E</contributor.author>
<contributor.author>Andreone, P</contributor.author>
<contributor.author>Cursaro, C</contributor.author>
<contributor.author>Barcena, R</contributor.author>
<contributor.author>Hoz, FG</contributor.author>
<contributor.author>Zachoval, R</contributor.author>
<contributor.author>Christina, M</contributor.author>
<contributor.author>De Man, RA</contributor.author>
<contributor.author>Metselaar, H</contributor.author>
<date.accessioned>2010-09-06T07:21:01Z</date.accessioned>
<date.available>2010-09-06T07:21:01Z</date.available>
<date.issued>2007</date.issued>
<identifier.citation>Liver Transplantation, 2007, v. 13 n. 3, p. 349-360</identifier.citation>
<identifier.issn>1527-6465</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/76418</identifier.uri>
<description.abstract>Wait-listed (n = 226) or post-liver transplantation (n = 241) chronic hepatitis B (CHB) patients with lamivudine-resistant hepatitis B virus (HBV) were treated with adefovir dipivoxil for a median of 39 and 99 weeks, respectively. Among wait-listed patients, serum HBV DNA levels became undetectable (&lt;l,000 copies/mL) in 59% and 65% at weeks 48 and 96, respectively. After 48 weeks, alanine aminotransferase (ALT), albumin, bilirubin, and prothrombin time normalized in 77%, 76%, 60%, and 84% of wait-listed patients, respectively. Among postransplantation patients, serum HBV DNA levels became undetectable in 40% and 65% at weeks 48 and 96, respectively. After 48 weeks, ALT, albumin, bilirubin, and prothrombin time normalized in 51%, 81%. 76%, and 56% of posttransplantation patients, respectively. Among wait-listed patients who underwent on-study liver transplantation, protection from graft reinfection over a median of 35 weeks was similar among parents who did (n = 34) or did not (n = 23) receive hepatitis B immunoglobulin (HBIg). Hepatitis B surface antigen was detected on the first measurement only in 6% and 9% of patiends who did or did not receive HBIg, respectively. Serum HBV DNA was detected on consecutive visits in 6% and 0% of patients who did or did not receive HBIg, respectively. Treatment-related adverse events led to discontinuation of adefovir dipivoxil in 4% of patients. Cumulative probabilities of resistance were 0%, 2%, and 2% at weeks 48, 96, and 144, respectively. In conclusion, adefovir dipivoxil is effective and safe at wait-listed or posttransplantation CHB patients with lamivudine-resistant HBV and prevents graft reinfection with or without HBIg. &#169; 2007 AASLD.</description.abstract>
<language>eng</language>
<publisher>John Wiley &amp; Sons, Inc. The Journal&apos;s web site is located at http://www3.interscience.wiley.com/cgi-bin/jtoc/106570021</publisher>
<relation.ispartof>Liver Transplantation</relation.ispartof>
<rights>Liver Transplantation. Copyright &#169; John Wiley &amp; Sons, Inc.</rights>
<subject.mesh>Adenine - adverse effects - analogs &amp; derivatives - therapeutic use</subject.mesh>
<subject.mesh>Adult</subject.mesh>
<subject.mesh>Antiviral Agents - adverse effects - therapeutic use</subject.mesh>
<subject.mesh>DNA, Viral - blood</subject.mesh>
<subject.mesh>Drug Resistance, Viral</subject.mesh>
<subject.mesh>Drug Therapy, Combination</subject.mesh>
<subject.mesh>Female</subject.mesh>
<subject.mesh>Hepatitis B - blood - drug therapy - prevention &amp; control</subject.mesh>
<subject.mesh>Hepatitis B virus - genetics</subject.mesh>
<subject.mesh>Humans</subject.mesh>
<subject.mesh>Kidney Diseases - chemically induced</subject.mesh>
<subject.mesh>Lamivudine - adverse effects - therapeutic use</subject.mesh>
<subject.mesh>Liver Transplantation - adverse effects - methods</subject.mesh>
<subject.mesh>Male</subject.mesh>
<subject.mesh>Middle Aged</subject.mesh>
<subject.mesh>Phosphonic Acids - adverse effects - therapeutic use</subject.mesh>
<subject.mesh>Prospective Studies</subject.mesh>
<subject.mesh>Recurrence - prevention &amp; control</subject.mesh>
<subject.mesh>Waiting Lists</subject.mesh>
<title>Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results</title>
<type>Article</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=1527-6465&amp;volume=13&amp;spage=349&amp;epage=360&amp;date=2007&amp;atitle=Adefovir+dipivoxil+for+wait-listed+and+post-liver+transplantation+patients+with+lamivudine-resistant+hepatitis+B:+final+long-term+results.</identifier.openurl>
<description.nature>Link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1002/lt.20981</identifier.doi>
<identifier.pmid>17326221</identifier.pmid>
<identifier.scopus>eid_2-s2.0-33947427581</identifier.scopus>
<identifier.hkuros>131794</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-33947427581&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>13</identifier.volume>
<identifier.issue>3</identifier.issue>
<identifier.spage>349</identifier.spage>
<identifier.epage>360</identifier.epage>
<identifier.isi>WOS:000244609200008</identifier.isi>
<publisher.place>United States</publisher.place>
</item>
Author Affiliations
  1. UCL
  2. Hopital Paul-Brousse
  3. University of California, San Francisco
  4. Scripps Green Hospital
  5. Università degli Studi di Padova
  6. Von-Bodelschwingh-Krankenhaus
  7. University of Tennessee Medical Group
  8. null
  9. University of Michigan Hospital
  10. University of Kentucky
  11. University of Miami
  12. Erasmus University Medical Center
  13. Mayo Clinic
  14. University Hospital
  15. Università degli Studi di Genova
  16. Hopital de Hautepierre
  17. Complejo Hospitalario Universitario de Santiago
  18. Azienda Ospedaliera Consorziale
  19. University of Iowa
  20. Hopital de La Conception
  21. The University of Hong Kong
  22. Universitätsklinikum Leipzig und Medizinische Fakultät
  23. Policlinico Universitario, Udine
  24. Royal Prince Alfred Hospital
  25. Cliniques Universitaires Saint-Luc, Brussels
  26. Hopital Saint-Luc
  27. University of Alberta
  28. University of Pittsburgh Medical Center
  29. Azienda Ospedaliero - Universitaria di Modena Policlinico
  30. Medizinische Hochschule Hannover (MHH)
  31. Alma Mater Studiorum Università di Bologna
  32. Medical College of Virginia
  33. Gilead Sciences Incorporated
  34. Ospedale Generale di Bolzano
  35. Mayo Clinic Scottsdale-Phoenix, Arizona
  36. null
  37. Toronto General Hospital
  38. Hospital Universitario La Fe
  39. Azienda Ospedaliera-Universitaria Pisana
  40. Queen Mary Hospital Hong Kong
  41. Ospedale S. Gionavvi Calibita
  42. University of Cambridge
  43. Universitätsklinikum Hamburg-Eppendorf und Medizinische Fakultät
  44. Auckland City Hospital
  45. Università degli Studi di Milano
  46. The Austin and Repatriation Medical Centre
  47. Klinikum der Universität München
  48. Hopital Saint-Eloi
  49. Hopital de l'Hotel-Dieu CHU Lyon
  50. null
  51. Lahey Clinic Medical Center, Burlington
  52. Hôpital Henri Mondor
  53. Western Attica General Hospital
  54. Royal Adelaide Hospital
  55. Cedars-Sinai Medical Center
  56. Hopital l'Archet
  57. University Hospital of Ghent
  58. Henry Dunant Hospital
  59. Hopital Beaujon
  60. Azienda Sanitaria Ospedaliera Molinette San Giovanni Battista Di Torino